Drug development is going from a marathon to a sprint

Taking stock of the drug industry, from the lab to the medicine chest

March 22, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

STAT STAT+ | Drug development was once a marathon. New tools and timelines are turning it into a sprint Leaders at Pfizer, Moderna, and FogPharma say mRNA and a new view of precision medicine have sped up biopharma drug development. By Elizabeth Cooney STAT+ | Despite new Wegovy coverage, Medicare patients may face high drug costs and other hurdles Medicare opens door to Wegovy coverage for heart benefits, but analysts warn patients are still likely to face high costs and other hurdles. By Elaine Chen Male birth control research wins audience over at STAT Madness event Current male birth control options are limited. Researchers are working on a new tack: a compound that stops sperm in its tracks. By Theresa Gaffney STAT STAT+ | How biotech investors spot opportunity when stocks are down — and up Drug pricing and promising science shape the decisions of biotech industry investors looking for companies to support. By Allison DeAngelis and Mario Aguilar STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser